The cytolytic and regulatory role of natural killer cells in experimental neoplasia.
NK cells are defined here as cells, other than macrophages and polymorphonuclear leucocytes, from non-immunized animals (or humans) which are cytotoxic for neoplastic and non-neoplastic targets in the absence of specific antibody. Though not requiring antibody, they may function as K cells in ADCC. This definition includes cells activated nonspecifically by such agents as IFN and IL-2. Murine NK cells may be subdivided into two types by differences in the kinetics of target-cell lysis. Those we label Type 1 correspond roughly to what others have called NKA, NKL or simply NK cells; those of Type 2 to NKB, NKS and NC cells. Type 1 cells express various antigens, including NK-1, Thy-1 (50%), Ly-1 (25%), Qa-3, Qa-4, Qa-5, Ly-5, Ly-6, Ly-10, Ly-11 and asialo-GM1, not expressed by Type 2 cells, whereas Mac-1 may be expressed by both types. At least some NK cells appear to be pre-thymic cells which, in the presence of a thymus, can differentiate into T cells. The level of NK activity is influenced by the age and genetic background of the mouse, the organ from which the cells are obtained, and a variety of experimental manipulations. Type 1 activity is increased by IFN and IL-2; Type 2 activity by IL-3. IFN appears to be concerned in the development of spontaneous NK activity in young mice. Many experiments have shown that NK cells may inhibit the growth of tumours which are sensitive to NK cells of the same type in vitro. Inhibitory cells which suppress NK activity may play an important regulatory role in vivo. There is still uncertainty about how NK cells recognize their targets. Possibilities discussed are: (1) specific interacting molecules; (2) more diffuse properties of target cell membranes; (3) absence of MHC-coded self-recognition markers. Certainly, the presence of a Class 1 MHC molecule is not necessary. NK killing appears to be mediated by cytotoxins released by NK cells. In vivo, NK cells contribute to limiting the development of transplanted and primary tumours, and metastasis from established tumours. NK cells seem well qualified to act as a first-line defence against neoplasia, and may kill cells not killed by T cells. Transfer of NK cells may be of value in the treatment of cancer.